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Background: Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic
progenitors and induces apoptosis in cancer cells.
Results: Ezatiostat was administered to 19 patients with non-deletion(5q) myelodysplastic syndrome (MDS) at one
of two doses (2000 mg or 2500 mg/day) in combination with 10 mg of lenalidomide on days 1–21 of a 28-day
cycle. No unexpected toxicities occurred and the incidence and severity of adverse events (AEs) were consistent
with that expected for each drug alone. The most common non-hematologic AEs related to ezatiostat in
combination with lenalidomide were mostly grade 1 and 2 fatigue, anorexia, nausea, diarrhea, and vomiting;
hematologic AEs due to lenalidomide were thrombocytopenia, neutropenia, and anemia. One of 4 evaluable
patients (25%) in the 2500/10 mg dose group experienced an erythroid hematologic improvement (HI-E) response
by 2006 MDS International Working Group (IWG) criteria. Four of 10 evaluable patients (40%) in the 2000 mg/10 mg
dose group experienced an HI-E response. Three of 7 (43%) red blood cell (RBC) transfusion-dependent patients
became RBC transfusion independent, including one patient for whom prior lenalidomide monotherapy was
ineffective. Three of 5 (60%) thrombocytopenic patients had an HI-platelet (HI-P) response. Bilineage HI-E and HI-P
responses occurred in 3 of 5 (60%), 1 of 3 with HI-E and HI-N (33%), and 1 of 3 with HI-N and HI-P (33%). One of 3
patients (33%) with pancytopenia experienced a complete trilineage response. All multilineage responses were
observed in the 2000/10 mg doses recommended for future studies.
Conclusions: The tolerability and activity profile of ezatiostat co-administered with lenalidomide supports the
further development of ezatiostat in combination with lenalidomide in MDS and also encourages studies of this
combination in other hematologic malignancies where lenalidomide is active.
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Myelodysplastic syndromes (MDS) represent a diverse
group of acquired hematopoietic stem cell disorders charac-
terized by ineffective hematopoiesis and a variable risk of
transformation to acute myeloid leukemia (AML) [1]. Prog-
nostically, MDS has been divided into two main groups
according to whether there is a higher or lower risk of
developing leukemia [2]. At diagnosis, two-thirds of MDS
patients present with lower-risk disease. A select group of
lower-risk patients with clonally restricted deletion of the
long arm of chromosome 5 (del[5q]) and transfusion-
dependent anemia respond to lenalidomide, but lenalido-
mide is less effective in the majority of patients with MDS
who lack del(5q) [3]. While the hypomethylating drugs aza-
citidine and decitabine are approved by the Food and Drug
Administration (FDA) for treatment of patients with a
broad range of MDS subtypes, the benefit of these agents
for lower-risk patients is not clearly established. Other ther-
apies that have been studied for treatment of MDS include
hematopoietic growth factors, immunosuppressive therapy,
various biologic response modifiers, and traditional cyto-
toxic chemotherapies; however, there remains a major need
for new treatment options.
Ezatiostat hydrochloride (Telintra), a glutathione-analog
reversible inhibitor of the enzyme glutathione S-transferase
P1-1 (GSTP1-1), is being developed for the treatment of
cytopenias associated with International Prognostic Scoring
System (IPSS) Low or Intermediate-1 risk MDS. Ezatiostat
facilitates dissociation of GSTP1-1 from jun-N-terminal
kinase (JNK), leading to activation of JNK and the subse-
quent promotion of growth and maturation of normal mul-
tilineage hematopoietic progenitors, while promoting
apoptosis in human leukemia blasts [4,5]. Recent reports
have shown that GSTP1-1 may be an important mediator
of signaling in hematopoietic cells [4]. In addition, the abil-
ity of ezatiostat to activate the caspase-dependent apoptotic
pathway may inhibit the emergence of malignant clones,
while ezatiostat's ability to increase reactive oxygen species
in dysplastic cells may contribute to apoptosis in dysplastic
cells [6]. These mechanistic features provide an attractive
profile for modulating the biology in MDS.
Recently, a randomized multicenter phase 2 study of eza-
tiostat was conducted in 89 heavily pretreated patients with
IPSS Low or Intermediate-1 risk MDS on two extended
dose schedules. In dose schedule 1, patients received ezatio-
stat at 1500 mg orally (PO) twice daily (b.i.d.) for 2 weeks
followed by a 1-week rest period in a 3-week treatment
cycle and in dose schedule 2, patients received ezatiostat at
1000 mg PO b.i.d. for 3 weeks followed by a 1-week rest
period in a 4-week treatment cycle. Multilineage
hematologic responses were seen and 29% of RBC-transfu-
sion-dependent patients experienced an erythroid response.
Ezatiostat had a very favorable tolerability profile, with
gastrointestinal side effects being the predominant adverseevent (AE); however, these were mainly restricted to grades
1 and 2, confirming the results of the prior studies. The
transfusion independence rate was higher (40%) in the sub-
set of patients previously treated with lenalidomide (and no
prior hypomethylating agents), suggesting a potential role
for combining the two drugs. Finally, since ezatiostat does
not have a myelosuppressive effect, it may act as a cytopro-
tective agent when used with lenalidomide, which is known
to be significantly myelotoxic. The doses selected for this
combination therapy study were selected based on the
results from the phase 2 single-agent ezatiostat study. [7]
The lenalidomide dose selected is based upon the approved
dose of lenalidomide for the treatment of MDS. [8] The
current phase 1 study was therefore conducted to determine
the safety and efficacy of ezatiostat in combination with
lenalidomide in IPSS Low and Intermediate-1 risk MDS
patients.
Materials and methods
This study was conducted in accordance with the Inter-
national Conference on Harmonization and Good Clin-
ical Practice standards. Institutional review board
approval was obtained from all participating institutions.
All patients provided written informed consent before
study participation.
Patient population
Eligible patients were 18 years or older, with histologically
confirmed diagnoses of non-del(5q) MDS, Low or Inter-
mediate-1 IPSS risk group, and Eastern Cooperative Oncol-
ogy Group performance status (ECOG PS) of 0 or 1. The
following World Health Organization (WHO) classification
MDS subtypes were included: refractory anemia (RA),
refractory nemia with excess blasts type I (RAEB-I), refrac-
tory anemia with ring sideroblasts (RARS), refractory
cytopenia with multilineage dysplasia (RCMD), refractory
cytopenia with multilineage dysplasia with ringed sidero-
blasts (RCMD-RS), MDS-unclassified (MDS-U), and MDS/
myeloproliferative neoplasm-unclassified (MDS/MPN-U)
without leukocytosis. Patients were required to have ad-
equate hepatic and renal function. Inclusion criteria allowed
multilineage cytopenias with assessment of response by
International Working Group (IWG) 2006 criteria [9],
<10% marrow blasts, and ineligibility or unwillingness to
undergo allogeneic stem cell transplantation. Patients were
excluded for prior allogeneic bone marrow transplantation,
a history of IPSS higher-risk MDS or of AML [10,11], prolif-
erative chronic myelomonocytic leukemia, use of oral corti-
costeroids at a dose exceeding 10 mg daily, history of
hepatitis B/C or human immunodeficiency virus, or an ac-
tive infection requiring intravenous antibiotics. Patients were
not allowed to receive hematopoietic growth factors while
on study, and a 4-week washout period for growth factors
and all prior MDS treatments was required before study
enrollment.
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This was a multicenter phase 1 dose-ranging study
evaluating ezatiostat in combination with lenalidomide
in patients with non-del(5q) IPSS Low or Intermediate-1
risk MDS. The hematologic improvement-erythroid (HI-
E), HI-Neutrophil (HI-N), and HI-Platelet (HI-P) rates
by IWG 2006 criteria and safety of each treatment group
were evaluated to select the optimal dose of ezatiostat in
combination with lenalidomide for future studies. Eza-
tiostat was given at a starting dose of 2000 mg total daily
in divided doses (1000 mg PO twice daily) in combin-
ation with lenalidomide at a starting dose of 10 mg PO
once daily on days 1–21 of a 28-day cycle. In each stage,
three to six patients in a standard 3 + 3 design were trea-
ted before escalation to the next higher dose level; stage
2 was an ezatiostat/lenalidomide 2500 mg/10 mg dose
level. Once dose-escalation was complete, the maximum
tolerated dose (MTD) cohort was expanded by an add-
itional 10 patients in stage 2. The primary objectives of
this study were to establish the MTD of ezatiostat in
combination with lenalidomide as well as to determine
the safety of the combination. The secondary objectives
of this study were to assess efficacy by determining rates
of HI-E, HI-N, and HI-P. Patients were treated until
MDS disease progression, lack of MDS response, un-
acceptable toxicities, or patient withdrawal from the
study.
Red blood cell (RBC) transfusion guidelines were pro-
vided in the protocol and RBC transfusions were to be
given for a hemoglobin (Hgb) level< 9.0 g/dL. All trea-
ted patients were monitored for safety and efficacy with
physical and laboratory examinations and hematologic
response assessments (IWG 2006) were evaluated every
two cycles [12]. Adverse events were graded in accord-
ance with the National Cancer Institute−Common Tox-
icity Criteria for Adverse Events, Version 3.0
(NCI−CTCAE, v3.0; Bethesda, MD) [13].
Drug formulation
Ezatiostat is formulated as 500 mg tablets. Each tablet
contains ezatiostat hydrochloride with the following
excipients: mannitol, croscarmellose sodium, hypromel-
lose, magnesium stearate, and Opadry Clear. Opradry
Clear is a mixture of hypromellose and polyethylene gly-
col 400.
Assessments
On day 1 of each treatment cycle, a physical examination
and laboratory assessments (complete blood count
[CBC] with differential and serum chemistry profile)
were obtained, use of concomitant medication(s) was
documented, AEs were assessed, and RBC transfusion
requirements were documented for the preceding 8-
week baseline period. CBC with differential and platelet
count was obtained weekly.Dose modifications
Patients who experienced a treatment-related non-
hematologic AE grade 3 or higher had treatment delayed
for up to 3 weeks or until recovery to grade 1 or base-
line, and subsequent treatment resumed at a dose
reduced by the amount of ezatiostat of 500 mg (1 tablet)
per day. If recovery did not occur after a delay of 21 days,
treatment was discontinued and patients were followed
until resolution of the AE. Patients were dosed at a start-
ing dose of lenalidomide (RevlimidW) at 10 mg using
commercial supply. If a patient experienced prolonged
thrombocytopenia and neutropenia, that patient's lenali-
domide dosage was adjusted per the lenalidomide pack-
age insert. Since lenalidomide is excreted by the kidney,
dose adjustments for renal impairment were made in ac-
cordance with the package insert.
Statistical analysis
Assuming the population incidence of an adverse event is
10% or higher, a sample size of 16 patients had a probabil-
ity of 82% of observing at least one adverse event. All en-
rolled patients were included in the intent-to-treat (ITT)
population. A secondary endpoint of the study was to de-
termine the HI response rate in the erythroid cell line (HI-
E) by the IWG MDS criteria (2006) in the ITT and effi-
cacy-evaluable (EE) populations. All enrolled patients who
received any amount of ezatiostat in combination with
lenalidomide treatment were included in the safety ana-
lysis. Patients who received at least two cycles of ezatiostat
in combination with lenalidomide treatment and for
whom an HI response assessment was completed were
included in the EE population. All investigator-determined
responses were independently reviewed and confirmed. Ef-
ficacy analyses were performed in the ITT and the EE
populations by the two dose groups. Exact binomial 95%
confidence intervals were provided for response rates.
Duration of response was estimated by Kaplan-Meier
method. HI-E is defined in the IWG 2006 criteria as RBC-
transfusion-dependent patients who experience a clinically
significant transfusion reduction by≥ 4 units from baseline
over 8 weeks after the initiation of study treatments (given
for Hgb< 9.0 g/dL); RBC transfusion independence is
defined as no RBC transfusions required over an 8-week
period. Time to HI-E response was calculated from the
day of the initiation of study treatment to the end day of
the 8-week period when an HI-E was declared. Time to
RBC-transfusion independence was calculated from the
day of the initiation of study treatment to the end day of
an 8-week period free of transfusions. Duration of HI-E re-
sponse was calculated from the end day of the 8-week
period when an HI-E was declared to the first day when
an HI-E criterion was no longer met. Duration of RBC-
transfusion independence was calculated from the last day
after an 8-week period free of transfusions to the date an
Table 1 Patient Demographics and MDS Disease
Characteristics
Age (years)
Median (range) 75 (57−82)
Age (years) N (%)
< 65 years 5 (26)
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definitions pertained only when transfusion reduction or
independence had been sustained beyond 8 weeks, per
IWG 2006 criteria.
The safety of ezatiostat in combination with lenalido-
mide was evaluated by determining the frequency, sever-
ity (NCI−CTCAE v3.0), and causal relationship(s) of
AEs that occurred during the treatment period and fol-
low-up period of 30 days from the last administration of
study drug treatment(s). The incidence and percentage
of AEs related to study treatment, as judged by investi-
gators, was reported by total daily dose levels of ezatio-
stat in combination with lenalidomide.0 13 (68)
1 6 (32)
IPSS Classification
Low Risk 5 (26)






RBC Transfusion Dependent 13 (68)
Median (Range) 6 (4−10)




RCMD 4 (21)Results and discussion
Patient demographics and MDS disease characteristics
Nineteen patients, 14 men (74%) and five women (26%),
median age 75 years (range 57–82), were treated in two
dose groups at nine centers in the United States between
June 1, 2010, and December 30, 2011. Patient demo-
graphics and MDS disease characteristics are shown in
Table 1. The majority of enrolled patients were in the
IPSS Intermediate-1 risk category 14 (74%). WHO sub-
types were a typical distribution for non-del(5q) MDS
population. Thirteen (68%) patients were RBC-transfu-
sion dependent and the median transfusion require-
ments were 6 units over an 8-week period (range 4–10).
Ten (53%) patients had bilineage or trilineage cytopenia.
Prior therapies are shown in Table 2. Ten (53%)
patients had received prior erythropoietin therapy. Three
(16%) patients had a history of failing to respond to prior




Unilineage Cytopenia 9 (47)
Bilineage Cytopenia 6 (32)
Trilineage Cytopenia 4 (21)
Baseline Cytopenia(s)
Anemia only 9 (47)
Anemia +Neutropenia 1 (5)
Anemia + Thrombocytopenia 5 (26)
Anemia +Neutropenia + Thrombocytopenia 4 (21)
Time from MDS Diagnosis (years)
Median (range) .9 (.10− 2.5)
Abbreviations: ECOG Eastern Cooperative Oncology Group; IPSS International
Prognostic Scoring System; RBC red blood cell; RA refractory anemia; RAEB-1 RA
with excess blasts, type 1; RCMD refractory cytopenia with multilineage dysplasia;
RCMD-RS RCMD with ringed sideroblasts; MDS-U myelodysplastic syndrome-
unclassified; MDS/MPN-U MDS/myeloproliferative neoplasm-unclassified.Ezatiostat in combination with lenalidomide treatments
administration
At the time of submission of this report, four patients are
continuing on extended therapy at the recommendation of
their investigator, due to continuing clinical benefit. A sum-
mary of treatment administration is shown in Table 3.
Lenalidomide dose reductions were infrequent, with only
9% of all cycles requiring dose reductions and 13% requir-
ing dose delays. Dose reductions were due to nausea (4
cycles), diarrhea (3 cycles), vomiting (4 cycles), neutropenia
(1 cycle), anxiety (2 cycles), and gastritis or acute renal in-
sufficiency (1 cycle). Dose delays were most frequently due
to thrombocytopenia and neutropenia. Two of six patients
reported dose-limiting toxicities, which consisted of grade 3
diarrhea and grade 3 rash; both were in the ezatiostat/lena-
lidomide 2500 mg/10 mg dose group. The ezatiostat/lenali-
domide 2000 mg/10 mg dose level was therefore selected as
the MTD for enrollment of 10 additional patients in stage
2. A total of 13 patients were treated at the 2000 mg/10 mg
combination dose level.
Table 2 Prior MDS Therapies
Treated Population (N = 19)










Abbreviations: G-CSF granulocyte colony stimulating factor.
Table 4 Adverse Events Related to Ezatiostat in
Combination with Lenalidomide for Both Dose Groups
Combined
NCI-CTCAE v3.0 Maximum Toxicity Grade (N = 19)
Adverse Event
(Preferred Term)
Grade 1 Grade 2 Grade 3 Grade 4 Total
n (%) n (%) n (%) n (%) n (%)
Hematologic (All Patients)
Thrombocytopenia 1 (5) 1 (5) 4 (21) 3 (16) 9 (47)
Neutropenia 0 2 (11) 2 (11) 2 (11) 6 (32)
Anemia 0 0 3 (16) 1 (5) 4 (21)
Febrile Neutropenia 0 0 2 (11) 0 2 (11)
Non-Hematologic (≥ 5% of Patients)
Diarrhoea 5 (26) 3 (16) 3 (16) 0 11 (58)
Nausea 7 (37) 3 (16) 1 (5) 0 11 (58)
Vomiting 6 (32) 4 (21) 1 (5) 0 11 (58)
Fatigue 1 (5) 5 (26) 0 0 6 (32)
Skin Odour Abnormal 3 (16) 1 (5) 0 0 4 (21)
Abdominal Pain Upper 2 (11) 1 (5) 0 0 3 (16)
Anorexia 2 (11) 1 (5) 0 0 3 (16)
Rash 0 1 (5) 2 (11) 0 3 (16)
Constipation 2 (11) 0 0 0 2 (11)
Flatulence 1 (5) 1 (5) 0 0 2 (11)
Muscle Spasms 1 (5) 0 1 (5) 0 2 (11)
Muscular Weakness 0 1 (5) 1 (5) 0 2 (11)
Oedema Peripheral 1 (5) 1 (5) 0 0 2 (11)
Abbreviations: NCI-CTCAE v3.0 National Cancer Institute−Common Toxicity
Criteria for Adverse Events, Version 3.0.
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Details of ezatiostat plus lenalidomide combination-
related adverse events by grade and combined dose levels
are presented in Table 4. No unexpected toxicities oc-
curred and the incidence and severity of AEs were consist-
ent with that expected for each drug alone. The most
common combination treatment-related non-hematologic
AEs in the combined dose levels were fatigue, anorexia,
nausea, diarrhea, and vomiting. There was one grade 4
event of hypersensitivity. The most common hematologic
treatment-related AEs were thrombocytopenia, neutro-
penia, and anemia, which are common with lenalidomide
and were rare in prior ezatiostat monotherapy studies.
There were two grade 3 febrile neutropenia events. Ezatio-
stat in combination with lenalidomide AEs by dose level
and frequency are presented in Table 5.
There were 16 combination treatment serious adverse
events (SAEs). Six events were assessed by the principal
investigator as related or possibly related to ezatiostat in
combination with lenalidomide treatment, including one





Safety Population 2000/10 mg 2500/10 mg Total
No. of Patients 13 6 19
Total No. of Cycles
Administered
56 23 79
Median No. of Cycles
per Patient (Range)
4 (1−14) 3.5 (1−7) 4 (1−14)
No. of Cycles with
Dose Reduction
(% of total cycles)
4 (7) 3 (13) 7 (9)
No. of Cycles
with Dose Delay
(% of total cycles)
7 (13) 3 (13) 10 (13)guaiac positive stools, febrile neutropenia, syncope, and
erosive gastritis. These events resolved without sequelae.Efficacy
Nineteen patients were in the treated population, and 14
of 19 patients were in the EE population. Of the 13 of 19
patients who were RBC-transfusion-dependent at enroll-
ment, 10 were treated at the 2000/10 mg dose level and
three treated at the 2500/10 mg dose level.
The majority of HI-E responders and all RBC-transfu-
sion-dependent patients who responded to combination
therapy were in the 2000/10 mg dose group. One of four
evaluable patients (25%) in the 2500/10 mg dose group
experienced an HI-E response (IWG 2006). Four of 10
evaluable patients (40%) in the 2000 mg/10 mg dose group
experienced an HI-E response. Three of seven evaluable
RBC-transfusion-dependent patients achieved RBC-trans-
fusion independence (43%; 95% CI, 0.8− 90.6%), including
one RBC-transfusion-independent patient who did not
previously respond to lenalidomide. Median duration of
transfusion independence has not yet been reached.
All multilineage responses were observed at the 2000/
10 mg dose level. In three of five (60%; 95% CI 14.7%
Table 5 Adverse Events Related to Ezatiostat in
Combination with Lenalidomide by Dose Level
Adverse Event
(Preferred Term)
Total Daily Starting Doses
Dose Group 1 Dose Group 2
2000/10 mg/day 2500/10 mg/day
(N= 13) (N= 6)
n (%) n (%)
Hematologic (All Patients)
Thrombocytopenia 7 (54) 2 (33)
Neutropenia 4 (31) 2 (33)
Anaemia 3 (23) 1 (17)
Febrile Neutropenia 2 (15) 0
Non-Hematologic (≥ 10% of Patients)
Vomiting 9 (69) 2 (33)
Diarrhea 8 (62) 3 (50)
Nausea 7 (54) 4 (67)
Fatigue 4 (31) 2 (33)
Abdominal Pain Upper 2 (15) 1 (17)
Constipation 2 (15) 0
Flatulence 2 (15) 0
Anorexia 2 (15) 1 (17)
Muscle Spasms 2 (15) 0
Muscle Weakness 2 (15) 0
Skin Odour Abnormal 3 (23) 1 (17)
Gastritis Erosive 0 1 (17)
Chills 0 1 (17)
Oedema Peripheral 1 (8) 1 (17)
Hypersensitivity 0 1 (17)
Occult Blood Positive 0 1 (17)
Gout 0 1 (17)
Flank Pain 0 1 (17)
Dysgeusia 0 1 (17)
Renal Failure Acute 0 1 (17)
Epitaxis 0 1 (17)
Rash 1 (8) 2 (33)
Night Sweats 0 1 (17)
Swelling Face 0 1 (17)
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response was observed, including one patient with plate-
let-transfusion dependence who achieved platelet-trans-
fusion independence. One of three patients with
neutropenia achieved an HI-N response, for an HI-N
rate in the eligible group of 33.3% (95% CI, 0.8−90.6%).
Bilineage responses included HI-E and HI-P responses
in three of five patients with both anemia and
thrombocytopenia (60%; 95% CI, 14.7%−94.7%); HI-E
and HI-N responses in one of three patients with both
anemia and neutropenia (33.3%; 95% CI, 0.8%−90.6%);and HI-N and HI-P responses in one of three patients
with both neutropenia and thrombocytopenia (33.3%;
95% CI, 0.8%−90.6%). One of three patients with triline-
age cytopenia had a complete response of all three cell
lineages (33.3%; 95% CI, 0.8%−90.6%) (Table 6). One of
three evaluable patients (33.3%) who had failed prior
lenalidomide therapy and was RBC-transfusion-
dependent became RBC-transfusion-independent. One
RBC- and platelet-transfusion-dependent patient who
had a poor response to prior anti-thymocyte-globulin
treatment achieved complete RBC- and platelet-transfu-
sion independence.
Discussion
Ezatiostat is the first GSTP1-1 inhibitor shown to cause
clinically significant reductions in RBC and platelet
transfusions, including transfusion independence, as well
as trilineage hematologic improvement—HI-E, HI-N and
HI-P—in single-agent monotherapy trials in patients
with IPSS Low or Intermediate-1 risk MDS [7,14,15],
thereby providing a unique profile of activity in MDS.
Since myelosuppression is a side effect common to
many of the available drugs for MDS, which exacerbates
disease-related cytopenias, the development of effective
combination chemotherapy regimens for the treatment
of lower risk MDS has been a challenge. Ezatiostat, with
its novel mechanism of action and its non-myelosup-
pressive single-agent activity, is a drug candidate for
combining with lenalidomide, with the possibility of im-
proving outcomes in these patients. The optimal dosing
for the combination regimen in this phase 1 trial was
determined to be ezatiostat at 2000 mg daily combined
with the standard 10 mg dose of lenalidomide days 1–21
in a 28-day cycle. The combination with lenalidomide
and ezatiostat showed promising hematopoietic-promot-
ing activity in non-del(5q) lower-risk MDS patients and
induced RBC-transfusion independence in patients who
were RBC-transfusion dependent. The combination also
induced platelet-transfusion independence in a patient
who was platelet-transfusion-dependent, an effect not
typically seen with lenalidomide monotherapy [16]. Trili-
neage and bilineage responses were also observed, as
seen previously with single-agent ezatiostat; again, multi-
lineage responses are uncommon with lenalidomide
monotherapy, which is most effective with respect to the
erythroid lineage. Interestingly, a patient who had failed
to respond to single-agent lenalidomide subsequently
responded to the combination of ezatiostat plus lenali-
domide. This observation may warrant further study.
Currently, ezatiostat is being evaluated in two phase 2
studies—a 150-patient clinical study in lenalidomide-re-
fractory or -resistant del(5q) MDS patients, and a 140-
patient phase 2b clinical study in non-del(5q) MDS










HI–E (%) (95% CI) (N= 13) (N =6)
4 (30.8) 1 (16.7)
(9.1−61.4) (0.4−64.1)
HI–N (%) (95% CI) (N= 3) (N=2)
1 (33.3) 0
(0.8−90.6) (0−84.2)
HI–P (%) (95% CI) (N= 5) (N=4)
3 (60) 0
(14.7−94.7) (0−60.2)
Platelet Transfusion Dependent (%) (N= 1) (N=1)
Platelet Transfusion Independent (%) 1 (100) 0 (0)










Bilineage (HI-N and HI-P) (%)
(95% CI)
(N= 3) (N=1)
1 (33.3) 0 (0)
(0.8−90.6) (0−97.5)
Trilineage





No. of RBC Transfusion
Dependent Patients (%)
10 (76.9) 3 (50)


















3 (60) 0 (0)
(14.7−94.7) (0−84.2)
Platelet Transfusion Dependent (N= 1) (N=0)
Platelet Transfusion Independent (%) 1 (100) 0 (0)
Bilineage (HI-E and HI-N) (%)
(95% CI)
(N= 3) (N=2)
1 (33.3) 0 (0)
(0.8−90.6) (0−84.2)
Table 6 Efficacy (Continued)
Bilineage (HI-E and HI-P) (%)
(95% CI)
(N= 5) (N=2)
3 (60) 0 (0)
(14.7−94.7) (0−84.2)
Bilineage (HI-N and HI-P) (%)
(95% CI)
(N= 3) (N=1)
1 (33.3) 0 (0)
(0.8−90.6) (0−97.5)
Trilineage (HI-E, HI-N, and HI-P) (%)
(95% CI)
(N= 3) (N=1)
1 (33.3) 0 (0)
(0.8−90.6) (0−97.5)
No. of RBC Transfusion Dependent Patients (%) 7 (70) 2 (50)




Abbreviations: HI-E hematologic improvement-erythroid; HI-N hematologic
improvement-neutrophil; HI-P hematologic improvement-platelet; CI
confidence interval; RBC red blood cell.
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that predict likelihood of response to ezatiostat was re-
cently reported [17]. The genomic marker results may
suggest the potential to develop a diagnostic test to
screen MDS patients most likely to respond to ezatiostat
and to utilize this test in a future trial to select patients for
study.
Conclusions
The tolerability and activity profile of ezatiostat co-admi-
nistered with lenalidomide suggests that this combin-
ation warrants further evaluation in future studies of
patients with IPSS Low or Intermediate-1 risk non-del
(5q) MDS and also encourages studies of this combin-
ation in other hematologic malignancies where lenalido-
mide is active.
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